Share of more than 70%! Class 8 drug market dominance has been present

In the rapid development of the pharmaceutical industry today, new drugs springing up, changing the global pharmaceutical market pattern. But in the Chinese market, there are areas that are temporarily almost monopolistic (the data are based on the 2015 retail price).is mainly used
type I. diabetes patients and 30-40% of type 2 diabetes patients. According to Zhongkang CMH statistics, the total market value of insulin preparations in 2015 reached 17.4 billion yuan. Noel and Nord, Lilly, Sanofi with its second and third generation of insulin preparation products accounted for 60%, 14%, 12% of the market, can be said to be the three dominant insulin preparations.
but in this field, domestic enterprises Tonghua Dongbao, Gan Li Pharmaceuticals, Fosun Group and other up-and-about shows have a gradual trend to replace imports. And domestic enterprises in the study of products will also enrich the current relatively single product line, for further competition in the insulin market to provide a follow-up force.nicotic acid lipid-lowering drugs (Aximos)
nicotic acid-lowering lipid drugs are mostly used in 2 with other blood-fat-lowering drugs, the market is smaller than other lipid-lowering drugs. Zhongkang CMH data show that in 2015 niphosphenic lipid-lowering drug market of about 260 million, Lunan Pharmaceuticals and China Resources Pharmaceuticals with a market share of 65%, 12% ranked first and second in the market. Lunan Pharmaceuticals' Aximos capsules and dispersal tablets went on sale earlier than Pfizer's, and Pfizer's Asimus is currently failing to stand out in the market.
last year, Lunan Pharmaceuticals submitted an application for registration of a new drug for aximos and Rishuvastatin compound release preparations, which are still under review, and it is not difficult to see Lunan Pharmaceuticals' determination to expand the product line of such drugs.β Sort blocker drug
β blocker is mainly used in all types of hypertension and angina and other diseases, a large number of products on the market, including Metolor, Bisololol, Propranolol, Eslow and so on. The drug had a market size of about $5.7 billion in 2015, with AstraZenecom and Merck accounting for 56% and 16% of the market, respectively.calcium phosphatase inhibitors (immunosuppressants)
calcium phosphatase inhibitors are clinically used for transplantation of immunity, and the products on the market are dominated by tekmos and cyclosporine. According to Zhongkang CMH monitoring, the market size of 4.8 billion yuan, Astellas and East China Pharmaceuticals with 53%, 18% of the market sales share ranked first and second. Among them, Astellas mainly with tekmos preparation products dominate the market, East China Pharmaceuticals product line covers cyclosporine, tekmos and siromos a variety of drugs.cellular venom immunosuppressants
cytotoxic immunosuppressants are mainly used in autoimmune diseases such as herpes, large herpes, systemic lupus erythematosus, psoriasis and so on. According to CMH data, the total market for cytotoxic immunosuppressants is about 2.8 billion yuan, and Roche and East China Pharmaceuticals have a near monopoly on the drug market. Roche accounts for nearly 79% of the market for McCormick capsules and tablets, while East China Pharmaceuticals accounts for 14%.M choline-receiving antagonists (anti-asthma drugs)
M choline-receiving antagonists are commonly used to treat asthma, listed products include pyrethroid ammonium powder inhaler, inhalation compound isopropyl bromide solution. Zhongkang CMH data show that the drug market is about 1.2 billion yuan in size. Grigg Ingeham has a market share of 82 per cent and Zheng Tianqing 16 per cent, a market that is almost monopolized by both. GriggIngham has five products under this category, and new products have been introduced in 2016, and the follow-up of new products has helped to strengthen its dominance.calcium steady-state medicine (osteopathic treatment drug)
calcium steady-state medicine belongs to orthopaedic drugs, products to salmon calcitonin-based, the market size of about 1.2 billion yuan. Salmon calcitonin is a peptide drug, currently mainly nasal sprays and injection forms. Novart has the largest market with a 57 per cent market share, followed by Beijing's Silver Valley with 15 per cent.the total market for malarial parasite drugs
antimalarial drugs is not large, only about 700 million yuan, Shanghai Pharmaceutical Group (market share of 84.2%) and Sanofi (market share of 15.5%) accounted for more than 99% of the market. The main products listed in antimalarial parasite drugs are hydroxychloroquine sulfate tablets, whose market is monopolized by Shanghai Pharmaceutical Group and Sanofi. (Zhongkang Research Institute)